Smith A G, Fan W, Regen L, Warnock S, Sprague M, Williams R, Nisperos B, Zhao L P, Loken M R, Hansen J A, Pereira S
Clinical Research Division, Fred Hutchinson Cancer Research Center, Seattle, WA, USA.
Tissue Antigens. 2012 May;79(5):359-66. doi: 10.1111/j.1399-0039.2012.01868.x.
Somatic mutations and genomic alterations are frequent events in the clonal evolution of hematologic malignancies. Recent studies have reported copy neutral loss of heterozygosity (LOH) for the mismatched human leukocyte antigen (HLA) haplotype in patients relapsed after haploidentical hematopoietic cell transplantation (HCT) for a hematologic malignancy. Herein, we report 15 cases of somatic mutations in the HLA genes of patients with a variety of hematologic diseases, including acute myelogenous leukemia, acute lymphocytic leukemia, chronic lymphocytic leukemia, chronic myeloid leukemia, myelodysplastic syndrome, and non-Hodgkin's lymphoma, encountered at our institute over the past decade. While two of the cases were identified in patient relapse specimens collected post-HCT, 13 cases were found in peripheral blood specimens submitted for HLA typing prior to transplantation. Ten patients exhibited acquired LOH for all or part of one HLA haplotype. Five other cases involved somatic mutations in the nucleotide sequences of common HLA-A or HLA-B alleles. Since they are not systematically evaluated prior to HCT, acquired mutations in HLA genes are likely under reported. Beyond the implications for accurate HLA typing and donor selection, alternations that result in the loss of HLA expression may allow escape from immune surveillance and adversely impact transplant outcome.
体细胞突变和基因组改变是血液系统恶性肿瘤克隆进化中的常见事件。最近的研究报道,在单倍体相合造血细胞移植(HCT)治疗血液系统恶性肿瘤后复发的患者中,错配的人类白细胞抗原(HLA)单倍型存在拷贝中性杂合性缺失(LOH)。在此,我们报告了过去十年在我们研究所遇到的15例患有各种血液系统疾病患者的HLA基因突变病例,这些疾病包括急性髓性白血病、急性淋巴细胞白血病、慢性淋巴细胞白血病、慢性粒细胞白血病、骨髓增生异常综合征和非霍奇金淋巴瘤。其中2例在HCT后采集的患者复发标本中被鉴定出来,13例在移植前提交用于HLA分型的外周血标本中被发现。10例患者出现了一个HLA单倍型全部或部分的获得性LOH。另外5例涉及常见HLA - A或HLA - B等位基因核苷酸序列的体细胞突变。由于在HCT前未对其进行系统评估,HLA基因的获得性突变可能未被充分报道。除了对准确的HLA分型和供体选择的影响外,导致HLA表达缺失的改变可能会使肿瘤逃避免疫监视,并对移植结果产生不利影响。